CH

Strength

汉肽实力

Hantide Zibo Company

汉肽生物淄博公司

BIOLOGICAL RESEARCH TEAM

生物研发组

A platform for the research and development of recombinant polypeptide drugs and a screening platform for novel anti-tumor drugs were established, and the fermentation technology of polyglutamic acid and antialcoholic bacteria was established.To complete the screening of glP-1 analogues;And eight patents for inventions.

2.jpg


PEPTIDE PROJECT TEAM

多肽研发组

The projects under development include Sting activator, polypeptide radioactive element complex, etc., teri vasopressin and its injection will be submitted for new drug registration application, and Ciconotone and Linalotide will be applied for clinical application.At the same time also developed 30 kinds of beauty peptide raw material production technology, ready to enter the "light medical beauty" market.

4.jpg

TIANJIN BRANCH OF HANTIDE BIOMEDICAL GROUP CO.,LTD.

Tianjin Branch of Hantide Biomedical Group Co., Ltd., established on August 10, 2020, is located in the United Novartis building, starfish Plaza, Tanggu marine science and Technology Park, Binhai New Area, Tianjin. The main business scope includes the development of a series of products such as common food, health food, essential oil, functional beverage, and antialcoholic peptide, as well as post marketing evaluation, product optimization and improvement, quality detection and analysis methodology development.

At the beginning of its establishment, Tianjin Branch established cooperative relations with Nankai University, Tianjin University of science and technology, Tianjin Modern Vocational and technical college, Tianshi University and other well-known universities, jointly committed to building a first-class product technology research and development platform, and promoting the construction of a large-scale scientific research mode of "production learning research marketing".

Tianjin branch undertakes the mission of improving the group's scientific research system and broadening the product strategic layout, and will gradually develop into a group strategic team with core scientific research ability.



版权所有 © 汉肽生物医药集团 鲁ICP备069573500456号

Scan follows the public account